Medium angle of pharmacist looking for prescription drugs on a shelf in a pharmacy.
Our Work

Latham Advises Cheplapharm on €950 Million High Yield Bond

February 9, 2026
Firm represents pharmaceutical company on the issuance of senior secured notes.

Latham & Watkins has advised Cheplapharm Arzneimittel GmbH (Cheplapharm), a leading international pharmaceutical platform for established branded medicines, on the issuance of €950 million aggregate principal amount of New York law 144A/Reg S senior secured notes due 2032. The senior secured notes will be listed on The International Stock Exchange (Official List).

The proceeds will be used to redeem Cheplapharm’s existing senior secured notes due 2028 in full and to partially repay amounts outstanding under its existing term loan facility.

The Latham team was led by Munich Capital Markets partner Rüdiger Malaun and Frankfurt Capital Markets partner Jan Penselin, with associates Peter Neuböck and Tobias Müller. Advice was also provided on tax matters by Munich partner Ulf Kieker.

Endnotes

    Contacts

    Malaun, Rüdiger

    Rüdiger Malaun

    Munich
    ruediger.malaun@lw.com +49.89.2080.3.8105
    Penselin, Jan

    Jan Penselin

    Frankfurt
    jan.penselin@lw.com +49.69.6062.6597